Showing results (141-150 of 166) with videos related to
Sort By:
Pageof 17
International Journal of Environmental Research and Public Health|September 28, 2021
Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction?Kenneth Blum, Mark S Gold, Luis Llanos-Gomez, et al.International Journal of Spine Surgery|July 11, 2025
Opioid-Induced Hyperalgesia and Inflammaging in the Management of Spine Pain: The Case for Genetically Directed Dopamine HomeostasisKai-Uwe Lewandrowski, Rossano Kepler Alvim Fiorelli, Sergio Schmidt, et al.Clinical and Experimental Psychology|June 26, 2023
Beyond Mor: Can Induction of Dopamine Homeostasis Along with Electrotherapy Attenuate the Opioid Crisis?Kenneth Blum, Abdalla Bowirrat, Eric R Braverman, et al.Journal of Personalized Medicine|December 29, 2022
Genetic Addiction Risk Severity Assessment Identifies Polymorphic Reward Genes as Antecedents to Reward Deficiency Syndrome (RDS) Hypodopaminergia's Effect on Addictive and Non-Addictive Behaviors in a Nuclear FamilyCatherine A Dennen, Kenneth Blum, Abdalla Bowirrat, et al.International Journal of Environmental Research and Public Health|November 13, 2021
Reward Deficiency Syndrome (RDS): A Cytoarchitectural Common Neurobiological Trait of All AddictionsKenneth Blum, Abdalla Bowirrat, Eric R Braverman, et al.Journal of Personalized Medicine|April 3, 2021
A Novel Precision Approach to Overcome the "Addiction Pandemic" by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis RestorationKenneth Blum, Shan Kazmi, Edward J Modestino, et al.Journal of Personalized Medicine|December 23, 2022
Theorizing the Role of Dopaminergic Polymorphic Risk Alleles with Intermittent Explosive Disorder (IED), Violent/Aggressive Behavior and Addiction: Justification of Genetic Addiction Risk Severity (GARS) TestingEdward Justin Modestino, Kenneth Blum, Catherine A Dennen, et al.Journal of Addiction Psychiatry|December 2, 2024
Is There a Natural, Non-addictive, and Non-anti-reward, Safe, Gene-based Solution to Treat Reward Deficiency Syndrome? KB220 Variants vs GLP-1 AnalogsEdward Justin Modestino, Abdalla Bowirrat, David Baron, et al.Journal of Personalized Medicine|October 27, 2022
Should Reward Deficiency Syndrome (RDS) Be Considered an Umbrella Disorder for Mental Illness and Associated Genetic and Epigenetic Induced Dysregulation of Brain Reward Circuitry?Kenneth Blum, Catherine A Dennen, Igor Elman, et al.Journal of Personalized Medicine|December 23, 2022
Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent OpioidsMauro Ceccanti, Kenneth Blum, Abdalla Bowirrat, et al.Pageof 17